News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
34.54
+0.70 (+2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Supernus Pharm
< Previous
1
2
Next >
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
October 17, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
October 10, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
September 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
August 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
August 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 02, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 01, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
April 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
PDUFA Target Action Date of April 5, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.